Abstract 1317: Biomarker evaluation for PD-1 targeted therapies in non-small cell lung cancer (NSCLC) patients
Alice O. Kamphorst(Icahn School of Medicine at Mount Sinai), Rafi Ahmed(Emory University), Gabriel Sica(Emory University), Lydia Koenig(Emory University), Fadlo R. Khuri(American University of Beirut Medical Center), Megan McCausland(Emory Healthcare), Suresh S. Ramalingam(Emory University), Rama Akondy(Emory University), Ke Yu(Emory University), Shu Yang(Central South University), Rathi N. Pillai(Emory University), Taofeek K. Owonikoko(UPMC Hillman Cancer Center)
Cited by 1
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Lineage relationship and protective immunity of memory CD8 T cell subsets
|Nature Immunology|2003|1.9k
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k